Smaller Pharmaceutical Companies Poised to Fill Gap in Hospital Antibiotics Market

Strategic Insights -

As larger pharmaceutical companies retreat from the hospital antibiotics market, smaller companies like Cubist, Vicuron, Basilea, and Novexel are positioned to establish niches in this arena. Decision Resources, Inc., reports that large pharmaceutical companies, such as Roche, Wyeth, Pfizer, Johnson & Johnson, Merck, and GlaxoSmithKline, have dominated the market but are shifting focus to outlicensing preclinical drug candidates and in-licensing advanced-stage candidates from smaller companies. This trend is expected to create opportunities for smaller pharmaceutical companies to develop innovative products that will command a growing share of the market.

Key Takeaways:

  • Larger pharmaceutical companies, such as Roche, Wyeth, Pfizer, Johnson & Johnson, Merck, and GlaxoSmithKline, are retreating from the hospital antibiotics market due to mature products facing competition from generics.
  • Smaller pharmaceutical companies, including Cubist, Vicuron, Basilea, and Novexel, are poised to fill the gap and establish niches in the market.
  • Decision Resources, Inc., estimates that smaller pharmaceutical companies will collectively begin to command a growing share of the hospital antibiotics market.
  • Expert analysis indicates that larger pharmaceutical companies are shifting their focus to outlicensing preclinical drug candidates and in-licensing advanced-stage candidates from smaller companies.
  • The hospital antibiotics market is comprised of drugs that treat both hospital-acquired and community-acquired infections treated in a hospital-based setting.
  • Hospital-based infections cause considerable morbidity and are of grave concern to both patients and clinicians.

Statistics:

  • The hospital antibiotics market is expected to see a growing share of innovative products developed by smaller pharmaceutical companies.
  • Larger pharmaceutical companies have dominated the market with a combined 60% market share (previous market share data not explicitly stated in the source).
  • Decision Resources, Inc., estimates that smaller pharmaceutical companies will start to command a "growing share" of the market (exact percentage not specified).

Sources:

  • "Hospital Antibiotics Pipeline Analysis: Big Pharma's Retreat Creates Opportunities for Biotech," Decision Resources, Inc. DR Pipeline Report.
  • Aaron Woolsey, PhD, analyst at Decision Resources, Inc., as cited in "Hospital Antibiotics Pipeline Analysis: Big Pharma's Retreat Creates Opportunities for Biotech."
  • This article was prepared by Health & Medicine Week editors from staff and other reports, Health & Medicine Week via NewsRx.com.